OncoSil Medical - trading halt pending announcement on Tripp-Ffx trial results and FDA correspondence

OncoSil Medical Limited (ASX: OSL) has announced a trading halt on its shares, pending the release of results from the TRIPP-FFX clinical trial and correspondence with the U.S. Food and Drug Administration (FDA). The company previously completed patient recruitment for the TRIPP-FFX study in July 2025, with data expected to become available in early 2026. The trial is evaluating OncoSil™ device in combination with FOLFIRINOX chemotherapy for patients with locally advanced pancreatic cancer (LAPC).

The TRIPP-FFX study is a prospective, multi-centre trial involving 88 patients across 15 hospitals in Europe and Australia. Its completion marked a significant milestone in the clinical development of the OncoSil™ device, with aim of expanding its use beyond existing indications. The study has drawn strong interest from clinicians and patients, contributing to an accelerated recruitment timeline.

OncoSil’s CEO, Nigel Lange, has emphasized the importance of the trial in demonstrating OncoSil™ device to improve outcomes for patients with LAPC. The company is also working to meet other development and commercialization milestones while awaiting the trial results.

The trading halt underscores the significance of the upcoming data release and potential regulatory developments. Investors are advised to monitor official announcements from the company for further updates.